The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance ...
Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor ...
An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results